Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
Theriva Biologics announced key clinical progress with the initiation of the VIRAGE2 Phase 2a trial evaluating more frequent dosing of its lead oncolytic adenovirus candidate, VCN-01, in metastatic pancreatic cancer. The company also discussed upcoming milestones, including a proposed Phase 2/3 trial for retinoblastoma and published positive Phase …